×

Business / Stock Market

Regenxbio Reveals Interim Data From Diabetic Retinopathy Gene Therapy Trial

Published Oct 11 2021 at 5:25 PM GMT

Business Insider

Business Insider @businessinsider.com

Add to Collections
Report Post

Continue reading at businessinsider.com

Key
Points

Regenxbio Inc (NASDAQ:RGNX) announced initial data from the Phase 2 ALTITUDE trial of RGX-314 for diabetic.

Credit

Tags

Continue reading at businessinsider.com

Posted in Business, Stock Market

Stats

Published Oct 11, 2021 5:25 PM GMT